Oral presentations by sessions

(vers. 19.08.2016)

Download the abstractbook here (higher resolution, 55 mb). Or with a lower resolution here (3 mb).

K1 Opening & Keynote Lecture I (plenary) Wednesday, 24 August 2016 13:00-13:45
		Welcome addresses
15 min		25th Anniversary of the European Congresses on Alternatives to Animal Testing in Linz, Austria Horst Spielmann, DE-Berlin
30 min		The 3Rs in relation to REACH Derek Knight, FI-Helsinki
K2 Keynote Lecture II (plenary) Thursday, 25 August 2016 09:00-09:30
30 min		Real world medicine and real world patients: Something that animal testing can never approximate Michael Liebmann, US-Kennett Square
K3 Keynote Lecture III (plenary) Friday, 26 August 2016 09:00-09:30
30 min		Combating infectious diseases, novel approaches and in vitro models Claus-Michael Lehr, DE-Saarbruecken
K4 Keynote Lecture IV (plenary) Saturday, 27 August 2016 09:00-09:30
30 min		The CRISPR/Cas9 sytstem: a game changer in the life sciences Malte Spielmann, DE-Berlin
1 EU 3Rs Projects in Toxicology & other 3Rs Funding Institutions Wednesday, 24 August 2016 13:50-15:20
30 min		SEURAT-1: A cluster of European projects that have changed the landscape for 21st century European toxicology Andrea-Nicole Richarz, IT-Ispra
30 min		The EU-ToxRisk project: A European flagship program for mechanism-based safety sciences and risk assessment Mardas Daneshian, DE-Konstanz
15 min		The Lush Prize - an overview Rebecca Ram, UK-Manchester
15 min		A retrospective on 40 years of funding animalfree methods Stefanie Schindler, CH-Bern
2 Global Cooperation on Implementing the 3Rs Wednesday, 24 August 2016 15:50-17:20
20 min		The current status of non-animal test methods and prospects for Asian cooperation Hajime Kojima, JP-Tokyo
20 min		The current status of nonanimal alternatives in the life sciences in China Mao Ling Wei, CN-Chengdu
20 min		Examination of the gap between validation and (real) regulatory acceptance Erin Hill, US-Gaithersburg
15 min		Norecopa: providing global 3R-resources for animal research Adrian Smith, NO-Oslo
15 min		MAD world? Promoting the greater mutual acceptance of data Jarlath Hynes, BE-Brussels
paid advertising
3 Ethical and Legal Issues Thursday, 25 August 2016 14:00-15:30
15 min		An ethical challenge to the normalisation of animal experimentation Kay Peggs, UK-Winchester
15 min		A proposal for a catalogue of criteria to objectify the harm-benefit analysis of proposed projects including animal experiments Norbert Alzmann, DR-Tuebingen
15 min		Applying the harm benefit assessment under the EU Directive – what does it mean in practice for animals? Katy Taylor, UK-London
15 min		Biotechnological chimeras and experimentation: legislative lacunae legerdemain? Maureen O'Sullivan, IR-Galway
15 min		Ethical aspects of the Crispr/Cas9 technology Henriette Bout, NL-Amsterdam
15 min		Non-human primates in neuroscience research: Can it be ethical, if it isn’t scientifically necessary? Jarrod Bailey, UK-London
4 Implementing Dir 2010/63/EU Thursday, 25 August 2016 09:35-11:10
20 min		The role of the National Committees (NC) and Animal Welfare Bodies (AWB) under Directive 2010/63/EU Susanna Louhimies, BE-Brussels
15 min		Towards a harmonized approach: Role of the German National Committee for the Protection of Animals Used for Scientific Purposes in the process of implementation of the Directive 2010/63/EU Justyna Chmielewska, DE-Berlin
15 min		Role of the Swedish national committee in the harmonization of project authorization and evaluation Katarina Cvek, SE-Uppsala
15 min		Establishing a culture of care by implementing AUGUST – a new and strong initiative at Aarhus University Birgitte Kousholt, DK-Aarhus N
15 min		From the guideline to the bench – The role of science based policy advice in implementing EU Dir 63/2010 in Germany Henning Steinicke, DE-Halle
15 min		Animal welfare requirements – significant room for improvement Irmela Ruhdel, DE-Neubiberg
5.1 Novel Approaches in Efficacy and Safety Testing – 3D models I Thursday, 25 August 2016 09:35-11:05
20 min		A three-dimensional bioprinted liver equivalent for human-on-a-chip toxicity screenings Tobias Grix, DE-Berlin
20 min		Studying liver toxicity and disease modelling using bioprinted 3D human liver tissue Christine Daly, UK-London
20 min		Hepatic differentiation of hiPSC in co-culture with endothelial cells using different culture media Nora Freyer, DE-Berlin
15 min		In vitro study of melatonin effect on HepG2 cells treated with IL-6 in newly developed liver on chip device Mi Jang, DE-Saarbruecken
15 min		A modular cell sheet-based approach towards 3D tissue models Marie Weinhart, DE-Berlin
5.2 Novel Approaches in Efficacy and Safety Testing – 3D models II Thursday, 25 August 2016 11:30-13:00
25 min		OncoCilAir™: Organotypic human in vitro model for lung cancer research Samuel Constant, CH-Plan-les-Ouates
20 min		Migrating to the 3rd dimension: the “Neurosphere Assay” to study migration disturbances during neurodevelopment Marta Barenys, DE-Duesseldorf
20 min		The 'Neurosphere Assay' as a valuable part of a DNT testing strategy Ellen Fritsche, DE-Duesseldorf
20 min		ATERA: advanced 3D human tissue models and exclusive testing services for cosmetic, consumer product and pharmaceutical industry Bart De Wever, LU-Esch-sur-Alzette
5.3 Novel Approaches in Efficacy and Safety Testing – Multi-Organ-Chips I Friday, 26 August 2016 09:35-11:05
20 min		From organoid technology to Multi-Organ-Chip development for substance testing Mark Rosowski, DE-Berlin
20 min		*Increasing biological relevance in vitro: From single microtissues to micro-physiological systems* Jens Kelm, CH-Zurich
20 min		Creating organotypic oxygen tension in cell culture chambers using perfused flow and flexible chamber geometry Kelly Davidge, UK-Rotherham
15 min		Online TEER measurements in Homunculus system for orally administered drugs testing Dmitry Sakharov, RU-Moscow
15 min		Utilization of Hommunculus platform for evaluation of cytochrome P450 activity in "liver-on-a-chip" Andrey Poloznikov, RU-Moscow
5.4 Novel Approaches in Efficacy and Safety Testing – Multi-Organ-Chips II Friday, 26 August 2016 11:30-13:00
20 min		*Bringing a human heart & fat on a chip: microphysiological platforms as in vitro* models of cardiac and adipose tissue Peter Loskill**, DE-Stuttgart
20 min		High-throughput microfluidic platform for culture of 3D-kidney tissue models Henriëtte Lanz, NL-Leiden
20 min		Towards lung disease-on-chip models and personalized medicine application Colette Bichsel, CH-Bern
15 min		Vascularization of Multi-Organ-Chips for tissue engineering and regenerative medicine Severin Mühleder, AT-Vienna
15 min		Opportunities for Organ-on-a-Chip models in toxicological risk assessment Minne Heringa, NL-Bilthoven
paid advertising
6.1 Stem Cells & Reproductive Toxicity (including mEST & hEST) - Stem Cells Thursday, 25 August 2016 11:30-13:00
20 min		Cardiotoxicity gene and miRNA biomarkers induced by anticancer drugs Agapios Sachinidis, DE-Cologne
20 min		Practical application of human iPS cells for chemical toxicity assessment Yasunari Kanda, JP-Tokyo
20 min		A hiPSC-based test platform (DropTech®) for toxicity assessment of small molecule compounds in early stage drug discovery Ole Pless, DE-Hamburg
15 min		Replacing animal testing by genotoxicity and carcinogenic cell transformation assessment using a tissue regenerating cell line from fish with GFP-labelled histones Petra Stahlschmidt-Allner, DE-Aarbergen
15 min		A stem cell based metabolic activation system – Potential for replacing rat liver S9 fraction Cristiano F. Lerche, DE-Aarbergen
6.2 Stem Cells & Reproductive Toxicity (including mEST & hEST) - EST Friday, 26 August 2016 14:00-15:30
20 min		Hand1-Luc Embryonic stem cell test (Hand1-Luc EST): A reporter gene assay using engineered mouse ES cells to evaluate embryotoxicity in vitro Florian Le Coz, JP-Osaka
20 min		Automation-compatible EST assay Simon Ströbel, CH-Schlieren
20 min		Prediction of relative developmental toxicity of antifungal compounds using the ES-D3 cell differentiation assay, combined with the BeWo transport model Hequn Li, UK-Sharnbrook
15 min		Tests for the safety evaluation of a Chinese herbal medicine formula used in the treatment of atopic dermatitis Lucia Lu Li, CN-Hangzhou
15 min		Good Cell Culture Practice for stem cells, stem-cell-derived models and organ-on-chip models Mardas Daneshian, DE-Konstanz
7.1 Refinement & Welfare: Culture of Care & Best Practice Approaches Thursday, 25 August 2016 14:00-15:30
15 min		Implementation of 3Rs for livestock animals in bioscientific research-rationale and objectives of the newly established expert working group – LaNiV Fabienne Ferrara, DE-Berlin
15 min		Group housing of rats and rabbits - Thinking out of the box Kerstin Kleinschmidt-Dörr, DE-Darmstadt
15 min		Refinement and reduction strategies in experimental stroke Christa Thöne-Reineke, DE-Berlin
15 min		The drinking water as application route for pain management in bone-linked mice models – Combining a refinement and a basic research study Annemarie Lang, DE-Berlin
15 min		Assessing laboratory mouse welfare using animal-based measures Elin Spangenberg, SE-Uppsala
15 min		Reducing animal numbers by half: A hybrid preparation technique for the simultaneous investigation of histology and broncho-alveolar lavage parameters of the rat lung Martin Wiemann, DE-Muenster
7.2 Refinement & Welfare: Avoidance of Severe Suffering Friday, 26 August 2016 11:30-13:00
20 min		Focus on severe suffering: an update on RSPCA activity to end severe suffering Elliot Lilley, UK-Horsham
20 min		Systematic reviews of animal studies equal the implementation of the 3Rs Merel Ritskes-Hoitinga, NL-Nijmegen
20 min		A proposal for a table to support the classification of the overall severity of a proposed project including animal experiments Norbert Alzmann, DE-Tuebingen
15 min		How to determine severity degrees for genetically altered rodents? Anne Zintsch, DE-Berlin
15 min		Repeated isoflurane anesthesia in female mice–Assessing the severity of stress Katharina Hohlbaum, DE-Berlin
paid advertising
8.1 Replacement of Animals in Research & Use of Non-Animal Methods and Technologies - NEW Non-Animal Methods Wednesday, 24 August 2016 13:50-15:20
15 min		Replacement and Non-Animal Methods: The importance to be the change Candida Nastrucci, IT-Rome
15 min		The process of isolation and characterisation of HUIEC - Human Intestinal Epithelial Cell Line Lidija Gradišnik, SL-Slovenia
15 min		Intestinal organoids: Functional studies on nutrient and drug transport, hormone secretion and intracellular signaling *Tamara Zietek*, DE-Munich
15 min		Replacement of goat xenobiotic metabolism studies beyond OCED 503 by use of rumen simulation technique (RUSITEC) Barbara Birk, DE-Ludwigshafen
15 min		Impact of New Technologies on Malignant Tumor Management and Therapy Lukas Kenner, AT-Vienna
15 min		*Three Rs in endocrine disruptor assessment – Refining sampling, reducing numbers of tested animals and replacing in vivo* testing Reinhard Möller**, DE-Aarbergen
8.2 Replacement of Animals in Research & Use of non-Animal Methods and Technologies - Serum Free Media Friday, 26 August 2016 09:35-11:05
20 min		Serum-free media and serum alternatives Jan van der Valk, NL-Utrecht
20 min		Towards the replacement of fetal bovine serum in cell culture applications Christopher Fassbender, UK-London
20 min		A fetal bovine serum free cytotoxicity test following ISO 10993-5 Joachim Wiest, DE-Munich
15 min		*IONOSENSE POC: Integration of OECTs with live cells an a 12-well plate for in vitro* diagnostics, Aimie Pavia**, FR-Gardanne
9.1 Predictive Toxicology - QSAR & Testing Strategies Thursday, 25 August 2016 09:35-11:05
20 min		OECD projects on Integrated Approaches to Testing and Assessment (IATA): a combination of mechanistic information and alternative methods to improve predictive toxicology Magdalini Sachana, FR-Paris
20 min		EuroMix: using (Q)SARs, TTC, molecular docking simulation and read across as a first tier in mixture toxicity risk assessment Emiel Rorije, NL-Bilthoven
20 min		A decision-making framework for the grouping and testing Josje Arts, NL-Arnhem
15 min		A High Accuracy QSAR based on rabbit data to predict the human skin and eye irritation potential of individual constituents and mixtures Faizan Sahigara, FR-L’Isle D’Abeau
15 min		Computational profiling as a proxy for drug hazard prediction in pharmaceutical research Friedemann Schmidt, DE-Frankfurt
9.2 Predictive Toxicology - Read Across Friday, 26 August 2016 16:00-17:30
20 min		*The use of metabolomics in vivo* as read across tool: a case study with phenoxy carboxylic acid herbicides Hennicke Kamp**, DE-Ludwigshafen
20 min		Supporting evidence in read across approaches: potential and limitations of new approaches and methodologies Eric Stilgenbauer, FI-Helsinki
20 min		Improving confidence in read across: A case study for the oral repeated dose toxicity of β-Olefinic alcohols Mark Cronin, UK-Liverpool
15 min		Simulating chemical kinetics and dynamics for the prediction of toxicity Alicia Paini, IT-Ispra
15 min		New possibilities in mathematical toxicology Marko Raseta, UK-York
paid advertising
10.1 Toxicology I - Systemic Toxicity & Environmental Toxicity Wednesday, 24 August 2016 13:50-15:20
20 min		EPAA contributions in the area of ADME and carcinogenicity testing Renate Weissenhorn, BE-Brussels
20 min		Exposure-Based Chemical Safety Assessment Workflow Integrating Alternative Methods: An Ab Initio Case Study for Repeated-Dose Toxicity Andrea-Nicole Richarz, IT-Ispra
20 min		Perspectives to use the fish embryo test for applications beyond acute toxicity prediction – chronic fish toxicity, endocrine disruption and developmental toxicity Stefan Scholz, DE-Leipzig
15 min		Human or mouse fibroblasts for assessing acute toxicity? Tuula Heinonen, FI-Tampere
15 min		A medium-throughput method for the analysis of (combinatorial) endocrine effects using the nematode C. elegans Silvia Vogl, DE-Berlin
10.2 Toxicology I - Inhalation Toxicity Friday, 26 August 2016 14:00-15:30
15 min		Evaluation of reconstituted human bronchial epithelium (MucilAir™) suitability for repeated dose testing Samuel Constant, CH-Plan-les-Ouates
15 min		Metaplastic phenotype in human primary bronchiolar epithelial cells after repeated exposure to mainstream cigarette smoke at the air-liquid interface Michaela Aufderheide, DE-Hannover
15 min		Establishment and charakterization of a lung/liver organ-on-a-chip model. Phase 1: Model charakterization David Bovard, CH-Neuchâtel
15 min		*Development of an in vitro* inhalation toxicity test with potential regulatory applicability Anna Maione**, US-Ashland MA
15 min		*Collaborative industry efforts to optimize and standardize in vitro* methods suitable for tobacco regulatory science Erin Hill**, US-Gaithersburg MD
15 min		Novel Aerosol exposure devices for in-vitro toxicity testing at the air/liquid interface Tobias Krebs, DE-Waldkirch
11.1 Toxicology II - Skin Sensitization, Phototoxicity Friday, 26 August 2016 09:35-11:05
20 min		Assessment of pre- and pro-haptens using non-animal test methods for skin sensitization Britta Wareing, DE-Ludwigshafen
20 min		Extending the limits of the hCLAT assay – test of the sensitization potential of oxidative hair dyes Karsten Mewes, DE-Duesseldorf
20 min		GARD – the future of sensitization testing using a genomics-based platform Anki Malmborg Hager, SE-Lund
15 min		ITS for skin sensitization potential – 1 out of 2 or 2 out of 3? David Roberts, UK-Liverpool
15 min		An improved reactive oxygen species assay for photosafety assessment of chemicals with limited aqueous solubility Yoshiki Seto, JP-Shizuoka
11.2 Toxicology II - Bio-barriers & Novel Testing Concepts Friday, 26 August 2016 16:00-17:30
20 min		Cellular and non-cellular elements of the pulmonary air-blood barrier Claus-Michael Lehr, DE-Saarbruecken
20 min		BioVaSc-TERM - a platform technology to engineer human barrier models Angela Rossi, DE-Wuerzburg
15 min		The novel ToxTracker reporter system provides mechanistic insight into the genotoxic properties of compounds and materials Giel Hendriks, NL-Leiden
15 min		Integration of conducting polymer devices with 3D human tissue models for in vitro toxicology testing Magali Ferro, FR-Gardanne
20 min		If non-animal alternative tests are accepted by regulatory agencies, will industry use them? Rodger Curren, US-Gaithersburg MD
paid advertising
12 Efficacy of Drugs, Biologiocals & Vaccines Thursday, 25 August 2016 11:30-13:00
20 min		Towards global harmonisation of 3Rs in biologicals Katrin Schutte, BE-Brussels
20 min		The “BINACLE” (binding and cleavage) assay allows in vitro determination of botulinum and tetanus neurotoxin activity Heike Behrensdorf-Nicol, DE-Langen
20 min		G-protein based ELISA as a potency test for human rabies vaccines Martine Chabaud-Riou, FR-Marcy l'Etoile
15 min		*Development, optimization and validation of an in vitro* skin irritation test for medical devices using the reconstructed human tissue model Epiderm Helena Kandarova**, SK-Bratislava
15 min		Animal Friendly Affinity Reagents (AFAs): making animal immunisation obsolete Alison Gray, FR-Morzine
13.1 *Disease Models in vitro* versus in vivo - Lung Infections** Thursday, 25 August 2016 14:00-15:30
20 min		Modeling severe infection in human lung tissue Katja Zscheppang, DE-Berlin
20 min		*The use of in vitro* human airway epithelia for the development of novel antivirals Samuel Constant**, CH-Plan-les-Ouates
20 min		*Novel cystic fibrosis in vitro* model for safety and efficacy testing of new drug delivery systems against chronic Pseudomonas aeruginosa infections Jenny Juntke**, DE-Saarbruecken
15 min		*Transient receptor potential (TRP) ion channels activation induce increased bronchoconstriction in passive sensitized vital human ex vivo* precision-cut lung slices Susann Dehmel**, DE-Hannover
15 min		Modeling fungal infections within a three-dimensional perfused respiratory system Doris Wilflingseder, AT-Innsbruck
13.2 Disease Models in vitro versus in vivo - Skin & ex vivo Tissues Wednesday, 24 August 2016 15:50-17:20
20 min		Inflammatory skin disease models Sarah Hedtrich, DE-Berlin
20 min		An inflammatory, filaggrin-deficient skin model demonstrates hallmarks of atopic dermatitis in vitro Stefan Hönzke, DE-Berlin
20 min		Novel perspectives for in vitro models of human skin wounds Maike Windbergs, DE-Saarbrücken
15 min		Fast and label-free tracking of cell behavior in non-animal models Karin Schütze, DE-Bernried
15 min		Preclinical evaluation of CD30 as a novel molecular target in systemic mastocytosis Peter Valent, AT-Vienna
*13.3 Disease Models in vitro* versus in vivo - Other Organs** Friday, 26 August 2016 14:00-15:30
20 min		*A human neuronal in vitro* model for application in biomedical research and in pharmacological and toxicological investigations Stefan Schildknecht**, DE-Konstanz
20 min		*3D in vitro* tissue models for infection studies with human pathogens Matthias Schweinlin**, DE-Wuerzburg
20 min		Retinal organotypic cultures as disease model for ophthalmic diseases – recently proposed models Sven Schnichels, DE-Tuebingen
15 min		*Analysis of a novel ex vivo* organ model to simulate neurodegeneration in retina Stephanie Joachim**, DE-Bochum
15 min		*Recent developments of disease and human in vitro* models of the blood-brain barrier Winfried Neuhaus**, AT-Vienna
*13.4 Disease Models in vitro* versus in vivo - Using Data Bases & Information Tools Friday, 26 August 2016 16:00-17:30**
25 min		Defining the optimal animal model for translational research using gene set enrichment analysis Matthias Steinfath, DE-Berlin
25 min		Modernizing law and policy to support innovation in preclinical pharmaceutical testing in the United States Elizabeth Baker, US-Washington
25 min		*From bedside to bench – adding human context to in vitro* models Brigitte Landesmann**, IT-Ispra
14.1 3Rs in Education and Academia - Academia Wednesday, 24 August 2016 15:50-17:20
25 min		BB3R – educating the next generation of scientists Monika Schäfer-Korting, DE-Berlin
20 min		ReThink3R – innovation strategies for young scientists – Report of the first workshop Annemarie Lang, DE-Berlin
15 min		CAAT Academy: From inception to launching Francois Busquet, BE-Ixelles
15 min		A Course in Replacement Alternatives: To give the good example Candida Nastrucci, IT-Rome
15 min		Improving transparency on quality and translatability of animal studies using new science driven approach Judith van Luijk, NL-Nijmegen
14.2 3Rs in Education and Academia - Education Friday, 26 August 2016 11:30-13:00
20 min		Teaching practical applications of animal welfare – a review over 10 years of the FELASA B-Course in Vienna Christiane Winding, AT-Vienna
20 min		Education and Training Platform for Laboratory Animal Science (ETPLAS) Jan van der Valk, NL-Utrecht
20 min		Development and establishment of an interdisciplinary international master program for laboratory animal science (MLAS): a contribution to the 3R principles Julia Steitz, DE-Aachen
15 min		Advanced training course for veterinarians to qualify for Animal Welfare Officer Christa Thöne-Reineke, DE-Berlin
15 min		Establishment of an education program that meets the needs of researchers and animals Jan Baumgart, DE-Mainz
15.1 Young Scientists Lectures I Saturday, 27 August 2016 09:30-11:15
15 min		The use of human (non- 3D equivalent) skin assays (SkimuneTM) for the detection of adverse reactions, potency and efficacy Ana Ribeiro, UK-Newcastle
15 min		An in vitro system to predict the pro-fibrotic potential of carbon nanotubes in the lung Hana Barosova, CH-Fribourg
15 min		Use of human derived liver cell lines for the detection of genotoxic carcinogens Monika Waldherr, AT-Vienna
15 min		Chronologically-aged fibroblasts significantly alter the morphology of reconstructed human skin Christian Hausmann, DE-Berlin
15 min		Three dimensional cell culture model for toxicity and efficacy tests Karolin Fröhlich, DE-Jena
15 min		Development of an innovative moving interface for an in vitro model of the epithelial intestinal barrier Joana Costa, IT-Massarosa
15 min		Label-free monitoring of HepG2 spheroids – a platform for automated liver toxicity screening Sebastian Eggert, DE-Munich
15.2 Young Scientists Lectures II Saturday, 27 August 2016 11:40-13:10
15 min		Characterization of reconstructed human skin containing Langerhans cells to monitor molecular events in skin sensitization Gerrit Müller, DE-Berlin
15 min		*A novel 3D in vitro* model of the deep lung in both healthy and diseased state for screening of safety and efficacy of pulmonary (nano)medicines Remi Hendrix**, DE-Saarbruecken
15 min		*Effects of anti-tumor drugs bevacizumab and cisplatin on cancer cell invaded human ex vivo* lung tissue in an organotypic model as an alternative to animal experiments Sebastian Konzok**, DE-Hannover
15 min		Safety assessment in EU-substance law: An open door for alternative methods Lena Hehemann, CH-Fribourg
15 min		Litter loss as a neglected welfare problem? Charlotte S. Leidinger, DE-Mainz
15 min		Assessment of Hen’s Egg Test Chorioallantoic Membrane (HET-CAM) for screening of anticancer activities of drugs Mahmoud Galal, EG-Cairo
R1 Round Table I - "Building a career in the 3Rs area: successful biotech SMEs" (plenary) Wednesday, 24 August 2016 17:25-18:25

R2 Round Table II - Implementing the concept of "Integrated Approaches to Testing and Assessment (IATA)" into international regulatory testing (plenary) Thursday, 25 August 2016 16:00-17:00

P1 Poster Session I Thursday, 25 August 2016 17:00-19:00
		Survey of the posters with presence of the authors. The titles and authors of this poster session I will be published separately. All posters will be present during all days of the congress.

P2 Poster Session II Friday, 26 August 2016 17:30-19:00
		Survey of the posters with presence of the authors. The titles and authors of this poster session II will be published separately. All posters will be present during all days of the congress.

Oral presentations by sessions

paid advertising

paid advertising

paid advertising

paid advertising

paid advertising